N-methyl-N-propan-2-ylpropane-2-sulfonamide | 691004-59-8

• 英文名称: N-methyl-N-propan-2-ylpropane-2-sulfonamide
• CAS: 691004-59-8
• 化学式: C₇H₁₇NO₂S
• 分子量: 179.283
• InChiKey: FTPVVASXYSIUGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES
  申请人：Euclises Pharmaceuticals, Inc.

  公开号：US20150197494A1

  公开（公告）日：2015-07-16

  The present invention provides NO-releasing nitrooxy-alkylene-linked-celecoxib conjugates, having the structure of Formula (I): wherein R 1 , R 2 , Q, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound of Formula (I); and methods useful for healing wounds, preventing and treating cancer, and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (I).

  本发明提供了NO释放的硝基氧烷基连接的Celecoxib共轭物，其具有如下式（I）的结构： 其中R1、R2、Q和L如详细描述中所定义；包含至少一种式（I）化合物的药物组合物；以及使用式（I）化合物有益于愈合伤口、预防和治疗癌症、治疗日光性角化症、囊性纤维化和痤疮的方法。
• METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS
  申请人：Polniaszek Richard

  公开号：US20100256366A1

  公开（公告）日：2010-10-07

  The invention provides methods and intermediates that are useful for preparing a compound of formula I: and salts thereof.

  本发明提供了用于制备公式I化合物的有用方法和中间体： 及其盐类。
• [EN] NOVEL PROTEIN KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PROTÉINES KINASES
  申请人：TENOVA PHARMACEUTICALS INC

  公开号：WO2021216440A1

  公开（公告）日：2021-10-28

  The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, conditions, or disorders, which respond to the inhibition of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) activity, or a combination thereof, are also described.

  本公开描述了新型蛋白激酶抑制剂以及其制备方法。还描述了包含这种蛋白激酶抑制剂的药物组合物，以及使用它们治疗对表皮生长因子受体（EGFR）、间变性淋巴瘤激酶（ALK）活性或二者组合的抑制有响应的癌症和其他疾病、症状或紊乱的方法。
• [EN] INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS DE PEPTIDYLARGININE DÉIMINASES
  申请人：GILEAD SCIENCES INC

  公开号：WO2022140390A1

  公开（公告）日：2022-06-30

  The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

  本公开涉及用于治疗与肽基精氨酸脱亚胺酶（PADs）相关的疾病（例如肽基精氨酸脱亚胺酶4型（PAD4））的新化合物。本公开还涉及用于制备这些化合物的过程和中间体，使用这些化合物的方法以及包含所述化合物的制药组合物。
• N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：US10398677B2

  公开（公告）日：2019-09-03

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  式 (I) 的 HBV 复制抑制剂 包括立体化学异构体形式及其盐类、水合物、溶液，其中 X、R1、R2、R3 和 R4 具有本文所定义的含义。 本发明还涉及制备所述化合物的工艺、含有这些化合物的药物组合物以及它们在 HBV 治疗中单独或与其他 HBV 抑制剂联合使用的情况。